

Date	Time	Track	Presentation Title	Speaker	
1-Jan	06:00 - 07:00 AM		3D-Micro Tissues in Translational Toxicology and Disease Modelling	Armin Wolf, PhD Chief Scientific Officer, InSphero AG	
1-Jan	-	Advancement of Biomarkers in Drug Development	CK18 as a Biomarker in NASH Clinical Trials	Jessica Tuohy, PhD Scientific Product Manager, DiaPharma Group, Inc.	
1-Jan	06:00 - 07:00 AM	in Early Phase	Generation of expanded primary liver cells	Astrid Nörenberg, PhD Managing Director, upcyte technologies GmbH	
1-Jan	-	New Practices in Early Phase Drug Discovery	Human Tissue models for better therapies	Sebastiaan Trietsch, PhD Chief Technology Officer, Mimetas -The Organ on a Chip Company	
1-Jan	-	Advancement of Biomarkers in Drug Development	Measuring What Matters: Proliferation and Cell Death Biomarkers for Oncology Research	Olivia Stricker, PhD Commercial Business Development Manager, Diapharma Group, Inc.	
1-Jan	06:00 - 07:00 AM	in Early Phase	Microfabricated Human Liver Tissues for Drug Development	Salman Khetani, PhD Associate Professor, Department of Bioengineering, University of Illinois at Chicago	
1-Jan	06:00 - 07:00 AM		Microphysiological Systems for Human Focused Drug Discovery	Tomasz Kostrzewski, PhD Director, Biology, CN Bio Innovations Limited	

1-Jan	06:00 - 07:00 AM	New Practices in Early Phase Drug Discovery	Organoids: A Revolutionary New Tool for Drug Screening	Rekha Pal, PhD Director, Scientific Engagement, Crown Bioscience, Inc.
1-Jan	-	Modern Approaches to Clinical Development	Uncovering the mechanism of stress-resistant DNA replication in cancer cells using a modern single-molecule technique	Chames Kermi, PhD, PharmD Postdoctoral Fellow, Chemical and Systems Biology, Stanford University School of Medicine
1-Jan	06:00 - 07:00 AM	New Practices in Early Phase Drug Discovery	Using 3D cell culture models and high content confocal imaging to evaluate efficacy and expose toxic liabilities in the drug development pipeline	Erin Edwards, PhD Head of Services, Visikol, Inc.
1-Jan	-	Advancement of Biomarkers in Drug Development	Vancomycin: How might Urinary Biomarkers and Precision Dosing create Precision Medicine for the most frequently utilized antibiotic in the hospital?	Marc H. Scheetz, PharmD, MSc, FCCP, FCP Associate Dean of Research and Professor, College of Pharmacy, Professor, College of Graduate Studies, Departments of Pharmacology and Biomedical Sciences, Director, Pharmacometrics Center of Excellence, Midwestern University
26-Feb	-	Modern Approaches to Clinical Development	Keynote Presentation: Discovery and Development of a Novel First-in-Class Resuscitative Agent	Professor Anil Gulati, MD, PhD Chairman & Chief Executive Officer of Pharmazz, Inc.; Adjunct Professor, Colleges of Pharmacy and Graduate Studies, Midwestern University; Department of Bioengineering, University of Illinois
26-Feb	-	Modern Approaches to Clinical Development	Keynote Presentation: Emerging Drug Combinations: Evolution From Pre-Clinical Discovery to Clinical Development	Khyati Shah, PhD Post Doctoral Research Scholar at University of California, San Francisco
26-Feb	-	Modern Approaches to Clinical Development	CRISPR Based Screening: Advantages of Transcriptional Activators and Inhibitors	Andrew Ravanelli, PhD Senior R&D Scientist, Genome and Epigenome Editing, MilliporeSigma
26-Feb	-	Modern Approaches to Clinical Development	QIAGEN CLC Genomics Workbench 20 - scalable software for NGS data analysis	Leif Schauser, PhD Director, Global Product Management, QIAGEN
26-Feb	12:00 - 01:00 PM	New Practices in Early Phase Drug Discovery	Characterizing the role of B cells in Response to Immunotherapy with the NanoString GeoMx Platform	Sarah Warren, PhD Senior Director of Advanced Applications, NanoString Technologies

26-Feb	- 02:30		Automated cell separation for drug discovery	Josh Mahlios, PhD Senior Marketing Product Manager, Miltenyi Biotec
--------	------------	--	--	--